ERBB2 and cancer: However, when addressing the proportions of Luminal B-like cancers in those with ER-positive, HER2-negative cancers, the proportion is similar for both groups (MBC: 67%, 40/60, female cancers: 62%, 269/437), providing rationale for the comparable 21-gene expression scores observed in both genders in this study.